These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 31711359)

  • 1. Cost-effectiveness of a melanoma screening programme using whole disease modelling.
    Buja A; Rivera M; Girardi G; Vecchiato A; Rebba V; Pizzo E; Sileni VC; Palozzo AC; Montesco M; Zorzi M; Sartor G; Scioni M; Bolzan M; Fiore PD; Bonavina MG; Rugge M; Baldo V; Rossi CR
    J Med Screen; 2020 Sep; 27(3):157-167. PubMed ID: 31711359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness Analysis of a Skin Awareness Intervention for Early Detection of Skin Cancer Targeting Men Older Than 50 Years.
    Gordon LG; Brynes J; Baade PD; Neale RE; Whiteman DC; Youl PH; Aitken JF; Janda M
    Value Health; 2017 Apr; 20(4):593-601. PubMed ID: 28408001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?
    Marcellusi A; Viti R; Damele F; Cammà C; Taliani G; Mennini FS
    Clin Drug Investig; 2016 Aug; 36(8):661-72. PubMed ID: 27234943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Melanoma Screening in Inflammatory Bowel Disease.
    Anderson AJM; Ferris LK; Binion DG; Smith KJ
    Dig Dis Sci; 2018 Oct; 63(10):2564-2572. PubMed ID: 29948569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling cost-effectiveness of cervical cancer screening in Hungary.
    Vokó Z; Nagyjánosi L; Margitai B; Kövi R; Tóth Z; László D; Kaló Z
    Value Health; 2012 Jan; 15(1):39-45. PubMed ID: 22264970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of the breast cancer screening programme in the Basque Country: retrospective cost-effectiveness and budget impact analysis.
    Arrospide A; Rue M; van Ravesteyn NT; Comas M; Soto-Gordoa M; Sarriugarte G; Mar J
    BMC Cancer; 2016 Jun; 16():344. PubMed ID: 27251556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melanoma screening: Informing public health policy with quantitative modelling.
    Gilmore S
    PLoS One; 2017; 12(9):e0182349. PubMed ID: 28945758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for Melanoma in Men: a Cost-Effectiveness Analysis.
    Adamson AS; Jarmul JA; Pignone MP
    J Gen Intern Med; 2020 Apr; 35(4):1175-1181. PubMed ID: 31705474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health system costs of skin cancer and cost-effectiveness of skin cancer prevention and screening: a systematic review.
    Gordon LG; Rowell D
    Eur J Cancer Prev; 2015 Mar; 24(2):141-9. PubMed ID: 25089375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of HPV-based cervical screening based on first year results in the Netherlands: a modelling study.
    Jansen E; Naber SK; Aitken CA; de Koning HJ; van Ballegooijen M; de Kok I
    BJOG; 2021 Feb; 128(3):573-582. PubMed ID: 32638462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Favorable incremental cost-effectiveness ratio for lung cancer screening in Italy.
    Veronesi G; Navone N; Novellis P; Dieci E; Toschi L; Velutti L; Solinas M; Vanni E; Alloisio M; Ghislandi S
    Lung Cancer; 2020 May; 143():73-79. PubMed ID: 32234647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of Prostate-Specific Antigen Screening Among Chinese Men.
    Zhao G; Shao Y; Zhang N; Wang J; Yuan L; Sun X; Shi L
    Value Health Reg Issues; 2020 May; 21():272-279. PubMed ID: 32402819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for Asymptomatic Coronary Artery Disease in Waitlisted Kidney Transplant Candidates: A Cost-Utility Analysis.
    Ying T; Tran A; Webster AC; Klarenbach SW; Gill J; Chadban S; Morton R
    Am J Kidney Dis; 2020 May; 75(5):693-704. PubMed ID: 31810731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality assurance target for community-based breast cancer screening in China: a model simulation.
    Yang L; Wang J; Cheng J; Wang Y; Lu W
    BMC Cancer; 2018 Mar; 18(1):261. PubMed ID: 29514679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic modelling of a public health programme for fall prevention.
    Farag I; Howard K; Ferreira ML; Sherrington C
    Age Ageing; 2015 May; 44(3):409-14. PubMed ID: 25523025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention versus early detection for long-term control of melanoma and keratinocyte carcinomas: a cost-effectiveness modelling study.
    Gordon L; Olsen C; Whiteman DC; Elliott TM; Janda M; Green A
    BMJ Open; 2020 Feb; 10(2):e034388. PubMed ID: 32107270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
    Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
    Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
    Murphy J; Halloran S; Gray A
    BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness and budget impact analysis of a population-based screening program for colorectal cancer.
    Pil L; Fobelets M; Putman K; Trybou J; Annemans L
    Eur J Intern Med; 2016 Jul; 32():72-8. PubMed ID: 27157827
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.